ESMO 2023: Tarlatamab Shows Promise for Small Cell Lung Cancer
MADRID, Spain — Despite the progress seen with the use of immunotherapy in recent years, only modest advances have been made in the field of small cell lung cancer, which represents 15% of all lung cancer diagnoses. Consequently, the positive results from the phase 2 study of tarlatamab in patients with small cell lung cancer (DeLLphi-301 study) have been met […]
Continue reading »